ReviewSeminars in nephrology2013
Chronic kidney disease: mineral and bone disorder in children.
Review in Seminars in nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Pooled it
- Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.PloS one · 2015Trial
- Pediatric osteoporosis: a comprehensive imaging-based review of diagnosis, differential diagnosis, and etiology.Skeletal radiology · 2026Review
- Diabetes and longitudinal changes in deep learning-derived measures of vertebral bone mineral density using conventional CT: the Multi-Ethnic Study of Atherosclerosis.Skeletal radiology · 2026Article
- Impact of online hemodiafiltration on bone turnover in children with CKD-5d: A prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia.The Journal of clinical endocrinology and metabolism · 2025Article
- Efficacy and safety of prophylactic intravenous calcium supplementation in patients with secondary hyperparathyroidism after parathyroidectomy: a retrospective study.Frontiers in endocrinology · 2025Article
- Pediatric CKD-MBD: existing and emerging treatment approaches.Pediatric nephrology (Berlin, Germany) · 2022Article
- Editorial: Mineral and Bone Disorder in CKD.Frontiers in pediatrics · 2022Article
- Mineral bone disorders and kidney disease in hospitalized children with sickle cell anemia.Frontiers in pediatrics · 2022Article
- Bone Quality in CKD Patients: Current Concepts and Future Directions - Part I.Kidney diseases (Basel, Switzerland) · 2021Review
- Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Article
- Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.British journal of clinical pharmacology · 2019Article
- High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats.Journal of bone and mineral metabolism · 2019Article
- An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.Pediatric nephrology (Berlin, Germany) · 2019Article
- The interplay between bone and vessels in pediatric CKD: lessons from a single-center study.Pediatric nephrology (Berlin, Germany) · 2018Article
- The Body-wide Transcriptome Landscape of Disease Models.iScience · 2018Article
- Assessment of Quality of Life among Children with End-Stage Renal Disease: A Cross-Sectional Study.Journal of environmental and public health · 2018Article
- Facial swelling in a child on chronic hemodialysis: Answers.Pediatric nephrology (Berlin, Germany) · 2017Article
- Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Childhood and adolescence are crucial times for the development of a healthy skeletal and cardiovascular system. Disordered mineral and bone metabolism accompany chronic kidney disease (CKD) and present significant obstacles to optimal bone strength, final adult height, and cardiovascular health. Early increases in bone and plasma fibroblast growth factor 23 (FGF23) are associated with early defects in skeletal mineralization. Later in the course of CKD, secondary hyperparathyroidism--caused by a combination of declining calcitriol values and phosphate retention--results in high-turnover renal osteodystrophy whereas increased levels of both phosphate and FGF23 contribute to cardiovascular disease. Treatment of hyperphosphatemia and secondary hyperparathyroidism improves high-turnover bone disease but fails to correct defects in skeletal mineralization. Because overtreatment may result in adynamic bone disease, growth failure, hypercalcemia, and progression of cardiovascular calcifications, therapy therefore must be titrated carefully to maintain optimal serum biochemical parameters according to stage of CKD. Newer therapeutic agents and new treatment paradigms may suppress serum PTH levels effectively while limiting intestinal calcium absorption and skeletal FGF23 stimulation and may provide future therapeutic alternatives for children with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.